Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease

Rejuvenation Research

Volumn 13, Issue 2-3, 2010, Pages 195-201

  Danielyan, Lusine ^a   Klein, Roman ^a   Hanson, Leah R ^b   Buadze, Marine ^a   Schwab, Matthias ^a,c   Gleiter, Christoph H ^a   Frey, William H ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Regions Hospital   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APELIN RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; LOSARTAN; PROTEIN P40; PROTEIN P70; TYROSINE 3 MONOOXYGENASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CORPUS STRIATUM; CYTOKINE PRODUCTION; FEMALE; LOCUS CERULEUS; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENILE PLAQUE; TRANSGENIC MOUSE; TREATMENT DURATION;

ADMINISTRATION, INTRANASAL; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOOD PRESSURE; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; LOSARTAN; MICE; MICE, TRANSGENIC; NEURONS; PRESENILIN-1; SENILE PLAQUES;

MUS; MUS MUSCULUS;

EID: 77952342062     PISSN: 15491684     EISSN: None     Source Type: Journal    
DOI: 10.1089/rej.2009.0944     Document Type: Article

References (27)

1. Savaskan E, Hock C, Olivieri G, Bruttel S, Rosenberg C, Hulette C, Muller-Spahn F. Cortical alterations of angioten-sin converting enzyme, angiotensin ii and at1 receptor in alzheimer's dementia. Neurobiol Aging 2001;22:541-546.
2. Barnes JM, Barnes NM, Costall B, Horovitz ZP, Naylor RJ. Angiotensin II inhibits the release of [3h]acetylcholine from rat entorhinal cortex in vitro. Brain Res 1989;491:136-143.
3. Fournier A, Oprisiu-Fournier R, Serot JM, Godefroy O, Achard JM, Faure S, Mazouz H, Temmar M, Albu A, Bordet R, Hanon O, Gueyffier F, Wang J, Black S, Sato N. Prevention of dementia by antihypertensive drugs: How at1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ace-inhibitors. Expert Rev Neurother 2009;9:1413-1431.
4. Wang JM, Tan J, Leenen FHH. Central nervous system 2: Blockade by peripheral administration of at1 receptor blockers. J Cardiovasc Pharmacol 2003;41:593-599.
5. Trenkwalder P. Potential for antihypertensive treatment with an at(1)-receptor blocker to reduce dementia in the elderly. J Hum Hypertens 2002;16(Suppl 3):S71.
6. Hanes DS, Weir MR. Usefulness of arbs and ace inhibitors in the prevention of vascular dementia in the elderly. Am J Geriatr Cardiol 2007;16:175-182.
7. Balin BJ, Broadwell RD, Salcman M, el Kalliny M. Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J Comp Neurol 1986;251:260-280.
8. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd. Delivery of insulin-like growth factor-i to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004;127: 481-496.
9. Hanson LR, 2nd Frey WH. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008;9(Suppl 3):S5.
10. Hadaczek P, Yamashita Y, Mirek H, Tamas L, Bohn MC, Noble C, Park JW, Bankiewicz K. The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol Ther 2006;14:69-78.
11. Danielyan L, Schafer R, von Ameln-Mayerhofer A, Buadze M, Geisler J, Klopfer T, Burkhardt U, Proksch B, Verleys-donk S, Ayturan M, Buniatian GH, Gleiter CH, Frey WH 2nd. Intranasal delivery of cells to the brain. Eur J Cell Biol 2009;88:315-324.
12. Staudacher T, Pech B, Tappe M, Gross G, Muhlbauer B, Luippold G. Arterial blood pressure and renal sodium excretion in dopamine d3 receptor knockout mice. Hypertens Res 2007;30:93-101.
13. Danielyan L, Lourhmati A, Verleysdonk S, Kabisch D, Proksch B, Thiess U, Umbreen S, Schmidt B, Gleiter CH. Angiotensin receptor type 1 blockade in astroglia decreases hypoxia-induced cell damage and TNF alpha release. Neu-rochem Res 2007;32:1489-1498.
14. Pourdjabbar A, Parker TG, Nguyen QT, Desjardins JF, La-pointe N, Tsoporis JN, Rouleau JL. Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: Effect of dose on survival, ventricular arrhythmias, function, and remodeling. Am J Physiol Heart Circ Physiol 2005; 288:H1997-H2005.
15. Hanson LR, Roeytenberg A, Martinez PM, Coppes VG, Sweet DC, Rao RJ, Marti DL, Hoekman JD, Matthews RB, Frey WH 2nd, Panter SS. Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J Pharmacol Exp Ther 2009;330:679-686.
16. Patel NS, Paris D, Mathura V, Quadros AN, Crawford FC, Mullan MJ. Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. J Neuroinflammation 2005;2:9.
17. Joglar B, Rodriguez-Pallares J, Rodriguez-Perez AI, Rey P, Guerra MJ, Labandeira-Garcia JL. The in-flammatory response in the mptp model of parkinson's disease is mediated by brain angiotensin: Relevance to progression of the disease. J Neurochem 2009;109:656-669.
18. Platten M, Youssef S, Hur EM, Ho PP, Han MH, Lanz TV, Phillips LK, Goldstein MJ, Bhat R, Raine CS, Sobel RA, Steinman L. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates th1-and th17-mediated autoimmunity. Proc Natl Acad Sci USA 2009; 106:14948-14953.
19. Zhao W, Wang J, Ho L, Ono K, Teplow DB, Pasinetti GM. Identification of antihypertensive drugs which inhibit amyloid-beta protein oligomerization. J Alzheimers Dis 2009;16:49-57.
20. Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, Humala N, Seror I, Bartholomew S, Rosendorff C, Pasinetti GM. Val-sartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of alzheimer disease. J Clin Invest 2007;117:3393-3402.
21. Zou K, Yamaguchi H, Akatsu H, Sakamoto T, Ko M, Mi-zoguchi K, Gong JS, Yu W, Yamamoto T, Kosaka K, Yana-gisawa K, Michikawa M. Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (abeta[1-42] to abeta[1-40]), and its inhibition enhances brain abeta deposition. J Neurosci 2007;27:8628-8635.
22. O'Neil JN, R Mouton P, Tizabi Y, Ottinger MA, Lei DL, Ingram DK, Manaye KF. Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP=PS1 mice. J Chem Neuroanat 2007;34:102-107.
23. Pugh PL, Vidgeon-Hart MP, Ashmeade T, Culbert AA, Zoe Seymour, Perren MJ, Joyce F, Bate ST, Babin A, Virley DJ, Richardson JC, Upton N, Sunter D. Repeated administration of the noradrenergic neurotoxin n-(2-chloroethyl)-n- ethyl-2-bromobenzylamine (dsp-4) modulates neuroinflammation and amyloid plaque load in mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. J Neuroin-flammation 2007;4:8.
24. Bondy B, Baghai TC, Zill P, Bottlender R, Jaeger M, Minov C, Schule C, Zwanzger P, Rupprecht R, Engel RR. Combined action of the ace d-and the g-protein beta3 t-allele in major depression: A possible link to cardiovascular disease? Mol Psychiatry 2002;7:1120-1126.
25. Saavedra JM, Benicky J, Zhou J. Angiotensin ii: multitasking in the brain. J Hypertens Suppl 2006; 24:S131-S137.
26. Domeney AM. Angiotensin converting enzyme inhibitors as potential cognitive enhancing agents. J Psychiatry Neurosci 1994;19:46-50.
27. Jenkins TA. Effect of angiotensin-related antihypertensives on brain neurotransmitter levels in rats. Neurosci Lett 2008;444:186-189.